UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended JuneSeptember 30, 2022
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

For the transition period from                     to                     .

Commission file number:  0-15586

U.S. NeuroSurgical Holdings, Inc.
(Exact name of registrant as specified in its charter)

Delaware
 47-5370333
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

2400 Research Blvd, Suite 325, Rockville, Maryland 20850
(Address of principal executive offices)

(301) 208-8998
(Registrant’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes  ☒ No  ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes  ☒ No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company, and “emerging growth company” in Rule 12b-2 of the Exchange Act.  (Check one):
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☐
Smaller reporting company ☒
     (do not check if a smaller reporting company)
Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      Yes  ☐          No  ☒

The number of shares of the registrant’s common stock, $0.01 par value, outstanding as of JuneSeptember 30, 2022 was 7,792,185.7,842,185.


Table of Contents

PART I - FINANCIAL INFORMATION
3
 
Item 1.
Financial Statements
3
 
Item 2.
Management Discussion and Analysis of Financial Condition and Results of Operations.
19
 
Item 3.
Quantitative and Qualitative Disclosures About Market Risk.
2324
 
Item 4.
Controls and Procedures
2324
PART II – OTHER INFORMATION
2526
 
Item 1.
Legal Proceedings
2526
 
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
2526
 
Item 3.
Defaults Upon Senior Securities
2526
 
Item 4.
Submission of Matters to a Vote of Security Holders
2526
 
Item 5.
Other Information
2526
 
Item 6.
Exhibits
2526
SIGNATURES
2627

2
Table of Contents
PART I - FINANCIAL INFORMATION

Item 1.Financial Statements
Item 1.  Financial Statements

U.S. NEUROSURGICAL HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

 September 30,  December 31, 
 2022  2021
 
June 30,
2022
(Unaudited)
  
December 31,
2021
(As Restated)
  (Unaudited)  
            
ASSETS            
Current assets:            
Cash and cash equivalents $1,096,000  $2,178,000  $651,000  $2,178,000 
Other current assets  57,000   65,000   52,000   65,000 
Total current assets  1,153,000   2,243,000   703,000   2,243,000 
                
Other assets:                
Due from related parties  1,000   930,000   9,000   930,000 
Investments in unconsolidated entities  150,000   141,000   152,000   141,000 
Goodwill  315,000   315,000   315,000   315,000 
Total other assets  466,000   1,386,000   476,000   1,386,000 
                
Property and equipment:                
Operating lease right-of-use asset  40,000   59,000   30,000   59,000 
Total property and equipment  40,000   59,000  
30,000   59,000 
  
      
     
TOTAL ASSETS $1,659,000  $3,688,000  $1,209,000  $3,688,000 
                
LIABILITIES                
Current liabilities:                
Operating lease right-of-use liability - current portion $
45,000  $43,000  $34,000  $43,000 
Accounts payable and accrued expenses  83,000   169,000   71,000   169,000 
Due to related parties
  47,000   0 
Income taxes payable  231,000   414,000   231,000   414,000 
Total current liabilities  406,000   626,000   336,000   626,000 
                
Operating lease right-of-use liability - net of current portion  0   23,000   -   23,000 
Guarantee liability  11,000   11,000   11,000   11,000 
Total liabilities  417,000   660,000   347,000   660,000 
                
EQUITY                
Common stock - par value $0.01; 25,000,000 shares authorized; 7,792,185 shares issued and outstanding at June 30, 2022 and December 31, 2021.
  78,000   78,000 
Common stock - par value $0.01; 25,000,000 shares authorized; 7,842,185 and 7,792,185 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively.
  78,000   78,000 
Additional paid-in capital  2,871,000   2,871,000   2,871,000   2,871,000 
Accumulated deficit
  (1,891,000)  (373,000)  (2,214,000)  (373,000)
U.S. NeuroSurgical Holdings Inc. stockholders’ equity
  1,058,000   2,576,000   735,000   2,576,000 
Noncontrolling interests  184,000   452,000   127,000   452,000 
Total equity  1,242,000   3,028,000   862,000   3,028,000 
TOTAL LIABILITIES AND EQUITY $1,659,000  $3,688,000  $1,209,000  $3,688,000 

The accompanying notes to condensed consolidated financial statements are an integral part hereof.

3
Table of Contents
U.S. NEUROSURGICAL HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

 Three Months Ended 
 September 30, 
Three Months Ended
June 30,
  2022  2021 
2022
2021
(As Restated)
     (Restated) 
      
Revenue$0$0  $-  $- 
         
Costs and expenses:         
Selling, general and administrative292,000249,000   221,000   268,000 
         
Total292,000249,000   221,000   268,000 
         
Operating loss
(292,000)(249,000)  (221,000)  (268,000)
         
Total other expense
         
Interest expense0(1,000)  -   - 
Other income  -   9,000 
Loss from investments in unconsolidated entities, net(998,000)(135,000)  (156,000)  (77,000)
Total other expense
(998,000)(136,000)  (156,000)  (68,000)
         
Loss before income taxes(1,290,000)(385,000)  (377,000)  (336,000)
         
Provision for income taxes1,000232,000   (1,000)  (16,000)
         
Net loss

(1,291,000)
(617,000)  (378,000)  (352,000)
Net loss attributable to noncontrolling interests
194,0000   57,000   - 
Net loss attributable to U.S. NeuroSurgical Holdings, Inc.$(1,097,000)$(617,000)
Net loss attributable to U.S. Neurosurgical Holdings, Inc. $(321,000) $(352,000)
         
Basic and diluted net loss per share attributable to U.S. NeuroSurgical Holdings, Inc.$(0.14)$(0.08) $(0.04) $(0.05)
         
Weighted average common shares outstanding, basic and diluted7,792,1857,792,185   7,792,185   7,792,185 

The accompanying notes to condensed consolidated financial statements are an integral part hereof.

4
Table of Contents
U.S. NEUROSURGICAL HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

 Nine Months Ended 
 September 30, 
 
Six Months Ended
June 30,
  2022  2021 
 2022
  
2021
(As Restated)
     (Restated) 
            
Revenue $0  $1,061,000  $-  $1,061,000 
                
Costs and expenses:                
Patient expenses  0   86,000   -   86,000 
Selling, general and administrative  652,000   547,000   878,000   815,000 
                
Total  652,000   633,000   878,000   901,000 
                
Operating (loss) income  (652,000)  428,000   (878,000)  160,000 
                
Total other (expense) income
                
Interest expense  0   (3,000)  -   (3,000)
Interest income - sales-type sublease  0   8,000   -   8,000 
Other income
  -   9,000 
Loss from investments in unconsolidated entities, net  (1,131,000)  (274,000)  (1,287,000)  (351,000)
Total other expense
  (1,131,000)  (269,000)  (1,287,000)  (337,000)
                
(Loss) income before income taxes  (1,783,000)  159,000   (2,165,000)  (177,000)
                
Provision for income taxes  3,000   484,000   (2,000)  (500,000)
                
Net loss
  (1,786,000)  (325,000)  (2,167,000)  (677,000)
Net loss attributable to noncontrolling interests  268,000   0   325,000   - 
Net loss attributable to U.S. NeuroSurgical Holdings, Inc. $(1,518,000) $(325,000)
Net loss attributable to U.S. Neurosurgical Holdings, Inc. $(1,842,000) $(677,000)
                
Basic and diluted net loss per share attributable to U.S. NeuroSurgical Holdings, Inc. $(0.19) $(0.04) $(0.24) $(0.09)
                
Weighted average common shares outstanding, basic and diluted  7,792,185   7,792,185   7,792,185   7,792,185 

The accompanying notes to condensed consolidated financial statements are an integral part hereof.

5
Table of Contents
U.S. NEUROSURGICAL HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

 Nine Months Ended 
 September 30, 
 
Six Months Ended
June 30,
  2022  
2021
 
 2022
  
2021
(As Restated)
     (Restated) 
            
Cash flows from operating activities:Cash flows from operating activities:    Cash flows from operating activities:    
Net loss
 $(1,786,000) $(325,000) $(2,167,000) $(677,000)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:                
Amortization of operating lease right-of-use asset  19,000   17,000   29,000   26,000 
Loss from investments in unconsolidated entities, net  1,131,000   274,000   1,287,000   350,000 
Distributed earnings from unconsolidated entities  11,000   0   11,000   - 
Deferred income taxes  -   (111,000)
Changes in:                
Accounts receivable  0   346,000   -   346,000 
Income taxes receivable/payable
  (183,000)  369,000 
Income taxes payable  (183,000)  496,000 
Other current assets  8,000   10,000   12,000   32,000 
Accounts payable and accrued expenses  (86,000)  (36,000)  (98,000)  10,000 
Operating lease right-of-use liability  (21,000)  (20,000)  (32,000)  (30,000)
Net cash (used in) provided by operating activities  (907,000)  635,000   (1,141,000)  442,000 
                
Cash flows from investing activities:Cash flows from investing activities:     Cash flows from investing activities:     
Advances to unconsolidated entities  (175,000)  (288,000)  (496,000)  (359,000)
Repayments from loans to unconsolidated entities  110,000   11,000 
Principal payments received under sales-type sublease  0   532,000   -   532,000 
Net cash (used in) provided by investing activities  (175,000)  244,000   (386,000)  184,000 
                
Cash flows from financing activities:Cash flows from financing activities:     Cash flows from financing activities:     
Repayment of finance lease obligations  0   (89,000)  -   (89,000)
Net cash used in financing activities  0   (89,000)  -   (89,000)
                
Net change in cash and cash equivalents  (1,082,000)  790,000   (1,527,000)  537,000 
Cash and cash equivalents - beginning of period  2,178,000   2,030,000   2,178,000   2,030,000 
Cash and cash equivalents - end of period $1,096,000  $2,820,000  $651,000  $2,567,000 
                
Supplemental disclosures of cash flow information:Supplemental disclosures of cash flow information: Supplemental disclosures of cash flow information: 
Cash paid for:                
Interest $0  $3,000  $-  $3,000 
Income taxes
 $183,000  $158,000  $-  $158,000 

The accompanying notes to condensed consolidated financial statements are an integral part hereof.

6
Table of Contents
U.S. NEUROSURGICAL HOLDINGS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


Note A - Basis of Preparation


The accompanying Condensed Consolidated Financial Statements of U.S. NeuroSurgical Holdings, Inc. and Subsidiaries (the “Company”) as of JuneSeptember 30, 2022, and 2021, are unaudited.  However, in the opinion of management, such statements include all adjustments necessary for a fair statement of the information presented therein.  The Consolidated Balance Sheet at December 31, 2021, has been derived from the audited Consolidated Financial Statements at that date appearing in the Company’s Annual Report on Form 10-K/A.


Pursuant to accounting requirements of the Securities and Exchange Commission applicable to quarterly reports on Form 10-Q, the accompanying Condensed Consolidated Financial Statements and notes do not include all disclosures required by accounting principles generally accepted in the United States of America for complete financial statements.  Accordingly, these statements should be read in conjunction with the Company’s most recent annual Consolidated Financial Statements.


Consolidated results of operations for interim periods are not necessarily indicative of those to be achieved for full fiscal years.  The only change to the Company’s equity in the three and sixnine months ended JuneSeptember 30, 2022, and 2021 was net loss for the periods.


The Company applies the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, Consolidation to noncontrolling interests in consolidated financial statements.  The guidance requires noncontrolling interests to be reported as a component of equity separate from the parent’s equity and purchases and sales of equity interests, that do not result in a change in control, to be accounted for as equity transactions.  In addition, net (loss) income attributable to noncontrolling interests are to be included in net (loss) income and, upon a loss of control, the interest sold, as well as any interest retained, is to be recorded at fair value, with any gain or loss recognized in net (loss) income.



The Company recognizes revenue in accordance with two different accounting standards: 1) Topic 606 and 2) Accounting Standards Codification (“ASC”) Topic 842, Leases.



The Company primarily generated revenue, in 2021, from a leasing arrangement with New York University, which is not within the scope of Revenue from Contracts with Customers (Topic 606), and from the sale of maintenance, under the same agreement, with a single performance obligation. The NYU agreement ended in March 2021.

The tables below present financial information associated with our leases.



Classification June 30, 2022
  June 30, 2021
 
Classification
 September 30,
 
Assets          2022  2021
 
Long-term                  
Operating lease assetsOperating lease right-of-use asset $40,000  $
77,000 Operating lease right-of-use asset $30,000  $
68,000 
Total leased assets   $40,000  $77,000    $30,000  $68,000 
                  
Liabilities                  
Current                  
Operating lease liabilitiesOperating lease right-of-use liability - current portion $
45,000  $
41,000 Operating lease right-of-use liability - current portion $
34,000  $
42,000 
                  
Long-term                  
Operating lease liabilitiesOperating lease right-of-use liability - net of current portion $
0  $
45,000 Operating lease right-of-use liability - net of current portion $
-  $
34,000 
Total lease liabilities   $45,000  $86,000    $34,000  $76,000 
                  
Lease Cost                  
Operating lease costSelling, general and administrative $21,000  $20,000 Selling, general and administrative $31,000  $31,000 
                  
Finance lease cost                  
Interest on lease liabilitiesInterest expense  0   2,000 Interest expense  -   2,000 
                  
Sublease incomeInterest income - sales-type sublease  0   8,000 Interest income - sales-type sublease  -   8,000 
Net lease expense  $21,000  $14,000  $31,000  $25,000

Maturity of lease liabilities (as of June 30, 2022)
 Operating lease 
Maturity of lease liabilities (as of September 30, 2022)
 Operating lease 
2022 $
23,000  $
11,000 
2023  24,000   24,000 
Total 
47,000  
35,000 
Less amount representing interest  2,000   1,000 
Present value of lease liabilities $45,000  $34,000 
Discount rate  5.850%  5.850%

8
Table of Contents
Note B – Gamma Knife at NYU Medical Center


U.S. NeuroSurgical, Inc. (“USN”), a wholly-owned subsidiary of U.S. NeuroSurgical Holdings, Inc. (“USNH”), opened a New York gamma knife treatment center in July 1997 on the campus of New York University (“NYU”) Medical Center.   The Company’s contract with NYU, its only customer, ended in March 2021.  Upon termination of the NYU contract, the Company recognized a gain of $100,000 relating to previously accrued expenses.  This gain was included as a reduction in selling, general and administrative expense in the quarter ended March 31, 2021.  The Company is actively seeking new business ventures and believes that its cash reserves, which are in excess of $1.0 million at June 30, 2022, will allow the Company the opportunity do so.ventures. Such plans include possible new operations or extensions of its activities in Florida and California, where it has established working relationships with physician groups, hospitals and other organizations.  In addition to these activities, the Company has been exploring possible combinations with other existing businesses that would create a larger operating entity that would better justify the expenses involved in continuing as an independent publicly traded company.

Note C – The Southern California Regional Gamma Knife Center
 

During 2007, the Company, through a noncontrolling interest in joint ventures, managed the formation of the Southern California Regional Gamma Knife Center at San Antonio Regional Hospital (“SARH”) in Upland, California.  Corona Gamma Knife, LLC (“CGK”) is party to a 14-year agreement with SARH to renovate space in the hospital and install and operate a Leksell PERFEXION gamma knife.  CGK leases the gamma knife from NeuroPartners LLC, which holds the gamma knife equipment.  In addition to returns on its ownership interests, USN Corona, Inc., (“USNC”), a wholly-owned subsidiary of USNH, expects to receive fees for management services relating to the facility.
 

USNC is a 20% owner of NeuroPartners LLC and owns 39% of CGK.
  

USNC was a 20% guarantor on NeuroPartners LLC’s seven-year lease with respect to the gamma knife equipment and certain leasehold improvements at SARH.  In February 2016, NeuroPartners LLC negotiated a new five-year lease to fund the reloading of cobalt and related construction services.  The new lease of $1,663,000 included a balance of $668,000 from the prior lease obligations.  This new lease was payable over 60 months.  The first payment of $31,000 was paid in April 2016 and the final payment was paid in March 2021, removing USNC’s guarantee obligation.
 

Construction of the SARH gamma knife center was completed in December 2008 and the first patient was treated in January 2009, at which time the 14-year gamma knife lease with SARH commenced.  The project has been funded principally by outside investors.  While the Company, through its joint ventures, has led the effort in organizing the business and overseeing the development and operation of the SARH center, its investment to date in the SARH center has been minimal.
 

At JuneSeptember 30, 2022 and December 31, 2021, the Company’s recorded investment (loss) of NeuroPartners LLC and CGK was $0 and ($10,000), respectively. For the sixnine months ended JuneSeptember 30, 2022, the Company’s equity in loss of NeuroPartners LLC and CGK was $28,000$110,000 compared to $7,000$22,000 for the sixnine months ended JuneSeptember 30, 2021.  At JuneSeptember 30, 2022, amounts due to related parties was $47,000$8,000 compared with $6,000 due from related parties at December 31, 2021.


9
Table of Contents

The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK:
 

NeuroPartners LLC and CGK Condensed Combined Income Statement Information
 
 Nine Months Ended 
 
Six Months Ended
June 30,
  September 30, 
 2022
  2021
  2022
  2021
 
            
Patient Revenue $277,000  $336,000  $242,000  $463,000 
                
Net (loss) income $(27,000) $27,000  $(215,000) $12,000 
     ��          
USNC’s equity in loss of NeuroPartners, LLC and CGK
 $(28,000) $(7,000) $(110,000) $(22,000)
 
 Three Months Ended 
 
Three Months Ended
June 30,
  September 30, 
 2022
  2021
  2022
  2021
 
            
Patient revenue $155,000  $170,000  $(36,000) $127,000 
                
Net income $3,000  $8,000 
Net (loss) income $(188,000) $(15,000)
                
USNC’s equity in loss of NeuroPartners LLC and CGK
 $(38,000) $(5,000) $(83,000) $(15,000)

NeuroPartners LLC and CGK Condensed Combined Balance Sheet Information

 
September 30,
  
December 31,
 
 
June 30,
2022
  
December 31,
2021
  2022  2021 
            
Current assets $370,000  $299,000  $226,000  $299,000 
                
Noncurrent assets  166,000   294,000   358,000   294,000 
                
Total assets $536,000  $593,000  $584,000  $593,000 
                
Current liabilities $535,000  $564,000  $942,000  $564,000 
                
Noncurrent liabilities  0   0   -   - 
                
Equity  1,000   29,000   (358,000)  29,000 
                
Total liabilities and equity $536,000  $593,000  $584,000  $593,000 
 

10
Table of Contents
Note D – Florida Oncology Partners


During 2010, through the formation of a joint venture, in which it had a noncontrolling interest, the Company expanded its market strategy to include opportunities to develop cancer centers featuring radiation therapy. In 2010, the Company formed FOP in partnership with local physicians and other investors. USNC owned a 24% interest in the venture. FOP abandoned its operations on June 28, 2019, due to continued losses at the site of operations and lack of success in good faith efforts to renegotiate an agreement with the party from whom FOP leased a facility and equipment, after several months of discussion.  Due to the circumstances, FOP derecognized the associated assets and liabilities and calculated a contingent liability equal to the net liabilities derecognized. On November 24, 2021, the lessor filed a Voluntary Motion to Dismiss its lawsuit against FOP, and on December 11, 2021, it was accepted and recorded by the court. There can be no guarantee the lessor will not reinstitute any future claims against FOP.
 

The Company’s recorded investment in FOP prior to dissolution had been reduced to 0zero due to losses incurred in prior years. NaNNo equity in earnings had been recorded by the Company due to FOP’s deficit equity.
 

On September 21, 2021, FOP filed Articles of Dissolution with the Florida Department of State that were recorded on September 22, 2021. FOP is now fully dissolved.

 


Note E – Boca Oncology Partners


During the quarter ended June 30, 2011, the Company, through the formation of a joint venture, in which it had a noncontrolling interest, participated in the formation of Boca Oncology Partners, LLC (“BOP”), for the purpose of owning and operating a cancer center in Boca Raton, Florida.  In June 2011, Boca Oncology Partners RE, LLC (“BOPRE”,) an affiliated entity, purchased a 20% interest in Boca West IMP, owner of a medical office building in West Boca, Florida in which BOP operates.  BOP occupies 6,000 square feet of the 32,000 square foot building.  The Company invested $225,000 initially and had a 22.5% interest in BOP and BOPRE. In February 2014, the Company and other members sold their interests in BOP.



In June 2012, BOPRE purchased an additional 3.75% of Boca West IMP from another investor bringing its total interest to 23.75%. BOPRE accounts for this investment under the cost method since it does not exercise significant influence over Boca West, IMP.



During the years ended December 31, 2018, and 2017, several investors relinquished part of their ownership interest in BOPRE, and those interests were distributed among the remaining investors in relationship to their percentages owned. During 2021 and 2022, additional members relinquished their ownership to USNC. As a result, the Company now holds a 24.36% ownership interest in BOPRE, which it accounts for under the equity method. The Company’s recorded investment in BOPRE is $150,000$152,000 and $151,000 at JuneSeptember 30, 2022 and December 31, 2021, respectively.


11
Table of Contents

The following tables present the summarized financial information of BOPRE:
 

BOPRE Condensed Income Statement Information


 
Nine Months Ended
 
 
Six Months Ended
June 30,
  September 30, 
 2022
  2021
  2022
  2021
 
            
Rental Income $0  $0  $-  $- 
                
Net income $31,000  $56,000  $52,000  $75,000 
                
USNC’s equity in earnings of BOPRE $8,000  $12,000  $8,000  $16,000 
 
 
Three Months Ended
 
 
Three Months Ended
June 30,
  September 30, 
 2022
  2021
  2022
  2021
 
            
Rental Income $0  $0  $-  $- 
                
Net income $14,000  $38,000  $16,000  $19,000 
                
USNC’s equity in earnings of BOPRE $4,000  $9,000  $2,000  $4,000 
 

BOPRE Condensed Balance Sheet Information


 
September 30,
 
December 31,
 
 
June 30,
2022
  
December 31,
2021
  2022
 2021
 
            
Current assets $94,000  $112,000  $110,000  $112,000 
                
Noncurrent assets  757,000   757,000   757,000   757,000 
                
Total assets $851,000  $869,000  $867,000  $869,000 
                
Current liabilities $0  $0  $-  $- 
                
Noncurrent liabilities  0   0   -   - 
                
Equity  851,000   869,000   867,000   869,000 
                
Total liabilities and equity $851,000  $869,000  $867,000  $869,000 
 

Note F - Medical Oncology Partners
 

In April 2015, Medical Oncology Partners, LLC (“MOP”), was formed in partnership with local physicians and other investors. MOP was established to acquire a 100% equity interest in United Oncology Medical Associates of Florida, LLC, (“UOMA”). USNC was not a member of MOP at the time of formation as it was not able to participate due to the fact that USNC was not a physician. Nevertheless, USNC wished to eventually obtain an equity interest in MOP and loaned Dr. Jaime Lozano, the principal investor in MOP and a co-investor in FOP, $173,000.  Dr. Lozano used these funds, along with an equal amount of his own funds (a total of $345,000), to purchase a 76.67% interest in MOP. Other investors paid a further $105,000 for the remaining equity in MOP. MOP used the $450,000 of financing to acquire a 100% equity interest in UOMA.  An application was filed for a waiver to allow USNC to hold an equity interest notwithstanding the physician requirement and on December 22, 2016, USNC was cleared to become a part owner of MOP. Dr. Lozano agreed to exchange half of his membership interest to USNC in settlement of the note to USNC.  USNC and Dr. Lozano also agreed to share equally in providing a 5% equity interest in MOP to an additional investor as a consulting fee for services rendered in the administration of MOP and UOMA. At December 22, 2016, USNC owned 35.83% of MOP with an initial carrying value of $161,000. The Company recorded its share of losses of $12,000 for the period from December 22, 2016, to December 31, 2016, against its investment which resulted in a reduction of its equity investment to $149,000.
  
12
Table of Contents

Due to increasing costs, continued net losses since April 2015, and reliance on related party and other debt for operating cash flows, the fair value of UOMA is less than its carrying amount. The Company tested its investment for impairment at December 31, 2016 and determined that the investment was impaired, and an impairment loss was recorded against the entire equity balance in MOP, as well as loans from USN and USNC to MOP and UOMA. For the sixnine months ended JuneSeptember 30, 2022, and 2021, the Company’s equity in loss of MOP was $92,000$211,000 and $34,000,$100,000, respectively, but was not recorded due to prior losses.
  

During the sixnine months ended JuneSeptember 30, 2022, and 2021, the Company advanced $189,000$259,000 and $277,000,$342,000, all of which has been fully impaired. These allowances and write offs were recorded as losses from investments in unconsolidated entities.
  

Due to loans made to MOP and UOMA, MOP and UOMA are considered to be variable interest entities of the Company.  However, as the Company is not deemed to be the primary beneficiary of MOP or UOMA, since it does not have the power to direct the operating activities that most significantly affect MOP’s or UOMA’s economic performance, the entities are not consolidated, but certain disclosures are provided herein.


13
Table of Contents

The following table presents the summarized financial information of MOP:
  

MOP Condensed Consolidated Income Statement Information


 Nine Months Ended 
 
Six Months Ended
June 30,
  September 30, 
 2022
  2021
  2022
  2021
 
            
Patient revenue $1,067,000  $1,068,000  $1,488,000  $1,601,000 
                
Net loss $(256,000) $(95,000) $(588,000) $(280,000)
                
USNC’s equity in loss in MOP
 $(92,000) $(34,000) $(211,000) $(100,000)
 
 Three Months Ended 
 
Three Months Ended
June 30,
  September 30, 
 2022
  2021
  2022
  2021
 
            
Patient revenue $534,000  $531,000  $439,000  $532,000 
                
Net loss $(68,000) $73,000 $(340,000) $(185,000)
                
USNC’s equity in loss of MOP
 $(53,000) $26,000 $(121,000) $(66,000)



MOP Condensed Consolidated Balance Sheet Information


 
September 30,
  
December 31,
 
 
June 30,
2022
  
December 31,
2021
  2022
  2021
 
            
Current assets $284,000  $201,000  $136,000  $201,000 
                
Noncurrent assets  241,000   384,000   162,000   384,000 
                
Total assets $525,000  $585,000  $298,000  $585,000 
                
Current liabilities $3,326,000  $3,109,000  $3,449,000  $3,109,000 
                
Noncurrent liabilities  64,000   92,000   50,000   92,000 
                
Deficit  (2,865,000)  (2,616,000)  (3,201,000)  (2,616,000)
                
Total liabilities and deficit $525,000  $585,000  $298,000  $585,000 


Note G - CB Oncology Partners
  

CBOP was organized September 1, 2017, to acquire the rights of a new cancer treatment center from FOP. USNC originally had a 24% equity interest in CBOP.  Beginning in October of 2017, CBOP began paying the remainder of the costs associated with opening the center. The medical center opened and treated its first patient in January of 2018.
  

Effective November 15, 2019, FOP transferred to, and CBOP assumed, a loan with BB&T bank, that it had entered into in order to finance the purchase of equipment and build out of the new center, as well as the associated property and equipment. In addition, CBOP and BB&T agreed to reduce the monthly loan repayments for the next nine months, and to extend the term of the loan from November 2024 to July 2025. In July 2020 CBOP and BB&T further agreed to reduce the monthly payments for the life of the loan and extended the loan to July of 2027.

14
Table of Contents

In June 2020, CBOP made a $500,000 capital call to its members. UNSC converted previously-madepreviously made advances totaling $121,000 into equity in CBOP to meet its capital requirement, and other members contributed $212,000 in cash. The remaining capital contributions are not expected to be met and, accordingly, the Company’s equity interest in CBOP increased to 28.58% in June 2020. For the nine months ended September 30, 2022, the Company’s equity in loss of CB was $111,000 compared to equity in earnings of $20,000 during the same period in the same period the prior year, but neither were recorded due to prior losses.
  

Amounts due from CBOP at JuneSeptember 30, 2022, totaled $2,211,000$2,716,000 of which all of it has been reserved against as of June 30,2022. These balances accrued interest at 6% per annum. Total accrued interest was $427,000 at June 30, 2022, and $335,000 at June 30, 2021, all of which has been fully reserved for. TheSeptember 30,2022.The Company records increases in the allowance as a component of loss from investments in unconsolidated entities and as a deduction in interest income for interest earned.entities.
  

Due to loans made to CBOP, CBOP is considered to be a variable interest entity of the Company.  However, as the Company is not deemed to be the primary beneficiary of CBOP, since it does not have the power to direct the operating activities that most significantly affect CBOP’s economic performance, the entity is not consolidated, but certain disclosures are provided herein.


15
Table of Contents

The following table presents the summarized financial information of CBOP:
  

CBOP Condensed Income Statement Information
  
 Nine Months Ended 
 
Six Months Ended
June 30,
  September 30, 
 2022
  2021
  2022
  2021
 
            
Patient revenue $1,026,000  $1,041,000  $1,507,000  $1,591,000 
                
Net (loss) income
 $(237,000) $92,000  $(387,000) $69,000 
                
USNC’s equity in (loss) income of CBOP
 $(68,000) $26,000  $(111,000) $20,000 
 
  
Three Months Ended
June 30,
 
  2022
  2021
 
       
Patient revenue $444,000  $570,000 
         
Net (loss) income
 $(191,000) $30,000
         
USNC’s equity in (loss) income of CBOP
 $(55,000) $8,000
  Three Months Ended 
  September 30, 
  2022
  2021
 
       
Patient revenue $482,000  $550,000 
         
Net loss
 $(158,000) $(23,000)
         
USNC’s equity in loss of CBOP
 $(45,000) $(7,000)


CBOP Condensed Balance Sheet Information
   
  June 30,
2022
  December 31,
2021
 
       
Current assets $526,000  $400,000 
         
Noncurrent assets  3,362,000   3,667,000 
         
Total assets $3,888,000  $4,067,000 
         
Current liabilities $3,826,000  $3,472,000 
         
Noncurrent liabilities  2,826,000   3,121,000 
         
Deficit  (2,764,000)  (2,526,000)
         
Total liabilities and deficit $3,888,000  $4,067,000 

  September 30,  December 31,
 
  2022
  2021
 
       
Current assets $444,000  $400,000 
         
Noncurrent assets  3,209,000   3,667,000 
         
Total assets $3,653,000  $4,067,000 
         
Current liabilities $3,598,000  $3,472,000 
         
Noncurrent liabilities  2,968,000   3,121,000 
         
Deficit  (2,913,000)  (2,526,000)
         
Total liabilities and deficit $3,653,000  $4,067,000 

16
Table of Contents
Note H – Elite Health


Effective October 1, 2021, U.S. NeuroSurgical, Inc. (“USN”), acquired all of the outstanding shares of capital stock of Elite Health Plan, Inc., a California corporation (“Elite Health”.) The transaction with Elite Health was structured as an investment by Elite Health shareholders in USN, and as such did not have an immediate effect on the percentage ownership of the shareholders of the Company.  However, the Company’s interest in USN, which currently holds substantially all of the interest in the Company’s businesses and operations, was effectively diluted by 15% as a result of the issuance of the new USN shares to the former shareholders of Elite Health.  In addition, pursuant to the terms of this transaction, the former shareholders of Elite Health may request that the Company take steps that would give such shareholders access to the public trading market.  If this is requested by the Elite Health shareholders, it could be accomplished at the Company’s election through an exchange of such shareholders’ shares in USN for common stock of the Company.


Elite Health is a private company with a limited operating history.  It was formed in 2017 with the purpose of establishing a managed care organization that will operate as a Medicare Advantage plan for seniors.  It is expected that Elite Health will operate in California, initially San Bernardino, Riverside, and Orange Counties, with the objective of addressing the growing number of Medicare eligible seniors in those markets.


Elite Health is in the process of applying for a Knox Keene license to operate a Medicare Advantage plan in California and has taken preliminary steps toward identifying a network of providers who are well-versed in the healthcare needs of seniors in the communities in which they practice.  If Elite Health is successful in obtaining the license, establishing Elite Health as an operating entity will require significant investment not currently available to the Company.  The Company is currently exploring opportunities to provide the necessary funding to proceed with activities required to launch Elite Health.

Note I – Income Taxes


The Company’s income tax rate, which includes federal and state income taxes, was approximately 0% and 304%174%, for the sixnine months ended JuneSeptember 30, 2022, and 2021, respectively. The Company recorded a tax charge of $3,000$2,000 and $484,000$500,000 for the sixnine months ended JuneSeptember 30, 2022, and 2021, respectively.

17
Table of Contents
Note J - Restatement of Previously Issued Financial Statements


During the quarter ended March 31, 2022, the Company determined that in March 2021, pursuant to an agreement with New York University ("NYU"(“NYU”), ownership of all of the gamma knife equipment at the NYU Medical Center transferred from the Company to NYU, resulting in the recognition of a gain on the sale and transfer of the gamma knife property on the Company'sCompany’s December 31, 2021 income tax returns. The Company previously received insurance proceeds with the Gamma Knife facility, which was destroyed as a result of flooding from Hurricane Sandy. For tax purposes, the resulting gain becomes taxable when the replacement property is sold or disposed of, which occurred in 2021. As a result, the Company recorded this tax liability and restated its consolidated financial statements as of and for the year ended December 31, 2021 and each of the quarters during the year ended December 31, 2021 on Form 10-K/A for the year ended December 31, 2021.

17
Table of Contents

The restatement tables below present a reconciliation from the previously reported to the restated values as of and for the three and sixnine months ended JuneSeptember 30, 2021. The values as previously reported were derived from the Quarterly Report on Form 10-Q for the quarter ended JuneSeptember 30, 2021 filed on August 11,November 19, 2021.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the Three Months Ended September 30, 2021

  As previously  Restatement    
  Reported  Impacts  As Restated 
Income tax provision $(8,000) $24,000  $16,000 
Net loss $(344,000) $(8,000) $(352,000)
Basic and diluted net loss per share $(0.04) $(0.01) $(0.05)

CONDENSED CONSOLIDATD STATEMENTS OF OPERATIONS
For the ThreeNine Months Ended June 30, 2021

  As previously  Restatement    
  Reported  Impacts  As Restated 
Income tax provision $189,000  $43,000  $232,000 
Net loss $(574,000) $(43,000) $(617,000)
Basic and diluted net loss per share $0.07  $(0.01) $(0.08)

CONDENSED CONSOLIDATD STATEMENTS OF OPERATIONS
For the Six Months Ended JuneSeptember 30, 2021

Income tax provision $194,000  $290,000  $484,000  $(202,000) $702,000  $500,000 
Net loss $(35,000) $(290,000) $(325,000) $(378,000) $(299,000) $(677,000)
Basic and diluted net loss per share $(0.00)
 $(0.04) $(0.04) $(0.05) $(0.04) $(0.09)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the SixNine Months Ended JuneSeptember 30, 2021

Net loss $(35,000) $(290,000) $(325,000)
Change in: Income taxes receivable/payable $0  $369,000  $369,000 
Deferred income taxes
 $79,000  $(79,000) $0 
Net loss $(378,000) $(299,000) $(677,000)
Change in: Income taxes receivable/payable $197,000  $299,000  $496,000 


18
Table of Contents
Item 2.Management Discussion and Analysis of Financial Condition and Results of Operations.

Critical Accounting Policies

The Condensed Consolidated Financial Statements of U.S. NeuroSurgical Holdings, Inc. and subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America.  As such, some accounting policies have a significant impact on amounts reported in the Condensed Consolidated Financial Statements.  A summary of those significant accounting policies can be found in Note B to the Consolidated Financial Statements, in our 2021 Annual Report on Form 10-K.  In particular, judgment is used in areas such as determining and assessing possible asset impairments, including investments in, and advances, to unconsolidated entities.

The following discussion and analysis provides information which the Company’s management believes is relevant to an assessment and understanding of the Company’s results of operations and financial condition. This discussion should be read in conjunction with the Condensed Consolidated Financial Statements and notes thereto appearing elsewhere herein.

19
Table of Contents
Recent events

The recent outbreak of the novel coronavirus COVID-19 has spread across the globe and has been declared a public health emergency by the World Health Organization and a National Emergency by the President of the United States.  Most states and municipalities in the U.S., including California, and Florida, have taken aggressive measures to reduce the spread of the disease, including limiting non-essential gatherings of people, ceasing all non-essential travel, ordering certain businesses and government agencies to cease non-essential operations at physical locations and issuing “shelter-in-place” orders, which direct individuals to shelter at their places of residence (subject to limited exceptions).  Across the healthcare industry, resources have been prioritized for the treatment and management of the outbreak.  Consequently, there have been delays in delivering radiation therapy treatments.  In addition, the COVID-19 pandemic poses the risk that the Company and its employees, contractors, customers, government and third party payors and others may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that have been and may continue to be requested or mandated by governmental authorities.

While the healthcare treatments that are provided by the Company are generally critical to the well-being of the patients it serves, a  sustained COVID-19 pandemic, and continued measures by the government and industry to contain the pandemic, could negatively impact results for the following reasons: (i) operations at medical facilities, including those operated by the Company, could be subject to reduced operation or prolonged closure; (ii) medical facilities may defer Gamma Knife and other cancer therapy treatments for non-urgent patient cases in order to allocate resources to the care of patients with COVID-19; (iii) patients may defer or cancel treatments due to real or perceived concerns about the potential spread of COVID-19 in a medical facility setting; (iv) the outbreak could materially impact operations for a sustained period of time due to the current travel bans and restrictions, quarantines, shelter-in-place orders and shutdowns; and/or (v) members of the Company’s workforce may become ill or have family members who are ill and are absent as a result, or they may elect not to come to work due to the illness affecting others in our office or facilities.

19
Table of Contents
The occurrence of any of the foregoing events could have a material adverse effect on our business, financial condition and results of operations. The COVID-19 outbreak and mitigation measures have had and may continue to have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition.  The extent to which the COVID-19 outbreak impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact. Although the Company’s contract with its only customer ended in March 2021, the Company is actively seeking new business ventures and believes that its cash reserves, which are in excess of $1 million at June 30, 2022, will allow the Company the opportunity do so.ventures.   Such plans include possible new operations or extensions of its activities in Florida and California, where it has established working relationships with physician groups, hospitals and other organizations.  In addition to these activities, the Company has been exploring possible combinations with other existing businesses that would create a larger operating entity that would better justify the expenses involved in continuing as an independent publicly traded company.

Results of Operations

Three Months Ended Junemonths ended September 30, 2022, Compared to Three Months Ended JuneSeptember 30, 2021

20
Table of Contents
Selling, general and administrative expense of $292,000$221,000 for the secondthird quarter of 2022 was 17% higherlower than the $249,000$268,000 incurred during the comparable period in 2021, due mostly to higherlower accounting and professional fees in\during the nine months ended September 30, 2022.

The Company incurred no interest expense in the secondthird quarter of 2022 and $1,000or in the comparable period in 2021.

During the three months ended JuneSeptember 30, 2022, the Company recognized a $998,000$156,000 loss from its investment in unconsolidated entities compared to a $135,000$77,000 loss during the same period in 2021. The higher current quarter loss is primarily due to the write off of advances made to CBOP.CBOP and MOP.

During the three months ended JuneSeptember 30, 2022, the Company recognized an income tax provisionexpense of $1,000 compared to an income tax provision of $232,000 (restated)$16,000 during the same period in 2021. The higher income tax charge in 2021 was due to the recognition of insurance proceeds and corresponding gain on the sale of the gamma knife.

For the three months ended JuneSeptember 30, 2022, the Company reported a net loss of $1,291,000$378,000 as compared to $617,000$352,000 for the same period a year earlier. The net loss was primarily due to the write off of advances to unconsolidated entities and the termination of the NYU contract.entities.

Six Months Ended JuneNine months ended September 30, 2022, Compared to SixNine Months Ended JuneSeptember 30, 20202021

Patient revenue for the sixnine months ended JuneSeptember 30, 2022, and 2021 was $0 and $1,061,000, respectively. Prior to the termination of the Company’s contract with NYU in March 2021, the Company’s Gamma Knife facility at NYU Medical Center represented all of the Company’s patient revenue.

Patient expenses for the sixnine months ended JuneSeptember 30, 2022, were $0 as compared to $86,000 reported for the comparable period in the previous year, primarily due to the effects of the NYU contract ending in March 2021.

20
Table of Contents
Selling, general and administrative expense of $652,000$878,000 for the first sixnine months ofended September 2022, was 19%8% higher than the $547,000$815,000 incurred during the comparable period in 2021, mainly due to due higher accounting and professional fees in 2022, offset by a $100,000 gain on termination of the NYU contract and the cancellation of the flood insurance policy for the NYU facility at March 31, 2021.

The Company incurred no interest expense in the first sixnine months of 2022 and $3,000 in the comparable period in 2021 related to finance leases.

The Company earned no interest income induring the first sixnine months of 2022ended September 302022, and $8,000 of interest income from its investment in a sales-type sublease for the sixnine months ended JuneSeptember 30, 2021.

During the sixnine months ended JuneSeptember 30, 2022, the Company recognized a $1,131,000$1,287,000 loss from its investment in unconsolidated entities compared to a $274,000$350,000 loss during the same period in 2021. The higher current year loss is primarily due to due to the write off of advances to CBOP in 2022.

21
Table of Contents
During the sixnine months ended JuneSeptember 30, 2022, the Company recognized an income tax provisionexpense of $3,000$2,000 compared to an income tax provision of $484,000 (restated)$500,000 during the same period in 2021.  The higher income tax charge in 2021 was due to the recognition of insurance proceeds and corresponding gain on the sale of the gamma knife.

For the sixnine months ended JuneSeptember 30, 2022, the Company reported a net loss of $1,786,000$2,167,000 as compared to $325,000$677,000 for the same period a year earlier. The higher net loss was primarily due to due to the write off of advances to unconsolidated entities and the cessation of the NYU contract in March 2021.

Liquidity and Capital Resources

At JuneSeptember 30, 2022, the Company had working capital of $747,000$367,000 as compared to $1,617,000 at December 31, 2021. Cash and cash equivalents at JuneSeptember 30, 2022 were $1,096,000$651,000 as compared to $2,178,000 at December 31, 2021.

Net cash used in operating activities for the sixnine months ended JuneSeptember 30, 2022, was $907,000$1,141,000 as compared to $635,000$442,000 provided by operating activities for the same period a year earlier. This change is primarily due to the termination of the NYU contract and the Company using cash reserves for day to day expenses. During the first sixnine months of 2022, the Company received $11,000 of distributed earnings from unconsolidated entities with no corresponding cash receipts in the first sixnine months of 2021.

With respect to investing activities, the Company made $175,000$496,000 of advances to unconsolidated entities during the sixnine months ended JuneSeptember 30, 2022, compared with $288,000$374,000 of loans and advances in the same period a year earlier to NeuroPartners LLC,NP, CGK, CBOP, and MOP to assist with business operations and working capital requirements. The Company also received $532,000 in principal payments under the NYU sales-type sublease in 2021, compared to $0 during the first sixnine months of 2022.

21
Table of Contents
With respect to financing activities, the Company’s contract with the NYU Medical Center ended in March 2021 along with all related lease arrangements.  The Company paid $89,000 towards its finance lease obligations during the sixnine months ended JuneSeptember 30, 2021.The Company is actively seeking new business ventures that could require investment beyond its current cash reserves.  Such plans include possible new operations or extensions of its activities in Florida and California, where it has established working relationships with physician groups, hospitals and other organizations.

Risk Factors

We desire to take advantage of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.  The factors listed under the caption “Risk Factors” in Annual Report on our Form 10-K for the fiscal year ended December 31, 2021, have affected or could affect our actual results and could cause such results to differ materially from those expressed in any forward-looking statements made by us.  Investors should carefully consider these risks and speculative factors inherent in and affecting our business and an investment in our common stock.

22
Table of Contents
Disclosure Regarding Forward Looking Statements

The Securities and Exchange Commission encourages companies to disclose forward looking information so that investors can better understand a company'scompany’s future prospects and make informed investment decisions.  This document contains such "forward-looking statements"“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, particularly statements anticipating future growth in revenues and cash flow.  Words such as "anticipates," "estimates," "expects," "projects," "targets," "intends," "plans," "believes," "will“anticipates,” “estimates,” “expects,” “projects,” “targets,” “intends,” “plans,” “believes,” “will be," "will” “will continue," "will” “will likely result,"” and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements.  Those forward-looking statements are based on management'smanagement’s present expectations about future events.  As with any projection or forecast, they are inherently susceptible to uncertainty and changes in circumstances, and the Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of such changes, new information, future events or otherwise.

The Company operates in a highly competitive and rapidly changing environment and in businesses that are dependent on our ability to: achieve profitability; increase revenues; sustain our current level of operations; maintain satisfactory relations with business partners; attract and retain key personnel; maintain and expand our strategic alliances; and protect our intellectual property.  The Company'sCompany’s actual results could differ materially from management'smanagement’s expectations because of changes in such factors.  New risk factors can arise and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company'sCompany’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

22
Table of Contents
Investors should also be aware that while the Company might, from time to time, communicate with securities analysts, it is against the Company'sCompany’s policy to disclose to them any material non-public information or other confidential commercial information. Accordingly, investors should not assume that the Company agrees with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, the Company has a policy against issuing or confirming financial forecasts or projections issued by others.  Thus, to the extent that reports issued by securities analysts or others contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

In addition, the Company’s overall financial strategy, including growth in operations, maintaining financial ratios and strengthening the balance sheet, could be adversely affected by increased interest rates, construction delays or other transactions, economic slowdowns and changes in the Company’s plans, strategies and intentions.

23
Table of Contents
Item 3.Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4.Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company'sCompany’s reports under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC'sSEC’s rules and forms, and that such information is accumulated and communicated to our management, as appropriate, to allow timely decisions regarding required disclosure.  Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.  We do realize that we are a very small company and as a small company with only the officers and directors participating in the day to day management, with the ability to override controls, each officer and director has multiple positions and responsibilities that would normally be distributed among several employees in larger organizations with adequate segregation of duties to ensure the appropriate checks and balances.  Because the Company does not currently have a separate chief financial officer, the Chief Executive Officer performs these functions with the support of one of the Company’s outside directors who assists in the reporting and disclosure process (the “Lead Director”).

Our management evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report.  Based upon that evaluation, the Company’s Chief Executive Officer concluded that the Company’s disclosure controls and procedures were not effective as of the end of the period covered by this report for the information required to be disclosed by the Company in the reports it files or submits under the Securities Exchange Act of 1934, as amended, to be recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, due to the material weakness in internal control over financial reporting described below.

23
Table of Contents
Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934).  Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.  The Company’s internal control over financial reporting includes those policies and procedures that:

24
Table of Contents
(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;

(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.

Our management assessed the effectiveness of the Company’s internal control over financial reporting as of JuneSeptember 30, 2022. A material weakness is a control deficiency, or a combination of control deficiencies in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. In connection with the assessment described above, management identified the following material weakness as of JuneSeptember 30, 2022: The Company did not maintain sufficient qualified personnel with the appropriate level of knowledge, experience and training in the application of accounting principles generally accepted in the United States of America and in internal controls over financial reporting commensurate with its financial reporting requirements. Specifically, effective controls were not designed and in place to ensure that the Company maintained, or had access to, appropriate resources with adequate experience and expertise in the area of financial reporting for transactions such as investments in unconsolidated entities, related party receivables, impairments, lease accounting, accounting for business combinations, income taxes, and to properly assess the application of new accounting pronouncements. The Company is in the process of developing efficient approaches to remediate this material weakness.  To do this in a cost-effective manner, considering the current extent of the Company’s operations, management is making arrangements with consultants and advisors to assist on an as-needed basis.

24
Table of Contents
Changes in Internal Control over Financial Reporting

While there have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended JuneSeptember 30, 2022, management is in the process of developing plans to remediate the material weakness identified above.

25
Table of Contents
PART II – OTHER INFORMATION

Item 1.Legal Proceedings

None

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3.Defaults Upon Senior Securities

Not applicable.

Item 4.Submission of Matters to a Vote of Security Holders

Not applicable.

Item 5.Other Information

Not applicable.

Item 6.Exhibits

31.1        Certification of President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

32.1        Certification of President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.

101         Interactive Data Files providing financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended JuneSeptember 30, 2022 in XBRL (eXtensible Business Reporting Language).  Pursuant to Regulation 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, and are otherwise not subject to liability.

2526
Table of Contents
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
U.S. NeuroSurgical Holdings, Inc.
 
(Registrant)
   
Date: August 12,November 21, 2022
By:
/s/ Alan Gold
 
  
Alan Gold
  
Director, President and
Chief Executive Officer
  
and

  
Principal Financial Officer
of the Registrant



26
27